Menopausal status-Postmenopausal Posts on Medivizor
Navigation Menu

Menopausal status-Postmenopausal Posts on Medivizor

Looking for postmenopausal women with advanced breast cancer to try a hormonal therapy

Posted by on Oct 24, 2019 in Breast cancer | 0 comments

In a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...

Read More

How effective is alpelisib in hormone-receptor positive breast cancer with PIK3CA-mutations?

Posted by on Aug 14, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness of alpelisib (Piqray) in hormone receptor-positive (HR+) -human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). They found that alpelisib significantly improved survival in patients with PIK3CA mutations.  Some background Breast cancer (BC) types can be...

Read More

Looking for patients with hormone-receptor positive breast cancer to test a new treatment combination

Posted by on Apr 24, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of durvalumab (Imfinzi) in combination with standard hormonal treatment for breast cancer (BC). The main outcome will be the response to treatment. The trial is recruiting in Tampa, Florida, US. The details Breast cancer (BC) is one of the most common cancers. It affects bothe...

Read More

Everolimus and exemstane for treatment of HR+/HER2- advanced or metastatic breast cancer

Posted by on Jul 16, 2018 in Breast cancer | 0 comments

In a nutshell This study looked at the effectiveness and safety of a combination of two cancer drugs, everolimus (Afinitor) and exemestane (Aromasin), in women after menopause with advanced breast cancer. The authors found that these drugs were safe and effective in the treatment of these women. Some background Breast cancer is...

Read More

Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.

Posted by on Feb 12, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if endocrine therapy (ET) is best used alone or with targeted therapy in the treatment of hormone positive, HER2 negative advanced breast cancer. The study found that patients who used ET and targeted therapy together experienced a better quality of life in some regards compared to ET used alone.  Some...

Read More

Fulvestrant: an option for estrogen-receptor positive breast cancer that has spread

Posted by on Aug 5, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare fulvestrant (Faslodex) to other standard endocrine agents in patients with advanced hormone sensitive breast cancer. This study concluded that fulvestrant was as effective as the available standard endocrine agents.  Some background Advanced hormone sensitive breast cancer (BC) is cancer that has...

Read More

The role of dexamethasone mouthwash in preventing everolimus-related stomatitis in women with breast cancer

Posted by on Apr 13, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated the use of dexamethasone (Ozurdex) mouthwash for preventing stomatitis in patients with breast cancer(BC).  The use of dexamethasone oral solution was found to significantly reduce the incidence and severity of stomatitis. Some background Everolimus (Afinitor) and exemestane (Aromasin) are mTOR inhibitors...

Read More

Adding bevacizumab to letrozole treatment in hormone receptor-positive metastatic breast cancer – A good idea?

Posted by on Jul 18, 2016 in Breast cancer | 0 comments

In a nutshell This study looked at the effect of adding bevacizumab (Avastin) to letrozole (Femara) treatment in patients with hormone receptor-positive (HR+) metastatic (spread to other areas) breast cancer. They found that bevacizumab treatment prolonged the amount of time before patients experienced worsening of their...

Read More